ChiCTR2200055822 版本V1.0 版本创建时间2022/01/20 09:29:41 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200055822 

最近更新日期:

Date of Last Refreshed on:

2022-01-20 09:29:10 

注册时间:

Date of Registration:

2022-01-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同卧位对中度ARDS经鼻高流量氧疗患者预后影响的研究

Public title:

Prognostic effects of different positions on patients with high flow nasal oxygen therapy with moderate ARDS

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同卧位对中度ARDS经鼻高流量氧疗患者预后影响的研究

Scientific title:

Prognostic effects of different positions on patients with high flow nasal oxygen therapy with moderate ARDS

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周锡鑫 

研究负责人:

周锡鑫 

Applicant:

Zhou Xixin 

Study leader:

Zhou Xixin 

申请注册联系人电话:

Applicant telephone:

63693734

研究负责人电话:

Study leader's telephone:

63693734

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

707365202@qq.com

研究负责人电子邮件:

Study leader's E-mail:

707365202@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区临江路74号

研究负责人通讯地址:

重庆市渝中区临江路74号

Applicant address:

No.74, Linjiang Road, Yuzhong District, Chongqing

Study leader's address:

No.74, Linjiang Road, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属第二医院

Applicant's institution:

the second affiliated hospital of Chongqing medical university

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第二医院

Primary sponsor:

The second affiliated hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区临江路76号

Primary sponsor's address:

No.76, Linjiang Road, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第二医院

具体地址:

渝中区临江路74号

Institution
hospital:

The Second Affiliated Hospital of Chongqing Medical University

Address:

76 Linjiang Road, Yuzhong District

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第二医院

具体地址:

南岸区茶园天文大道288号

Institution
hospital:

The Second Affiliated Hospital of Chongqing Medical University

Address:

288 Astronomical Avenue, Tea Garden, Nanan District

经费或物资来源:

自费

Source(s) of funding:

at our own expense

Target disease:

acute respiratory distress syndrome

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(1)探索俯卧位和侧卧位对经鼻高流量中度ARDS患者插管率和死亡率的影响 (2)探索出更实用,患者耐受性更高且能改善患者预后的体位  

Objectives of Study:

(1) To explore the effect of prone and lateral position on intubation rate and mortality in patients in patients in moderate ARDS (2) To explore body positions that are more practical, have higher patient tolerance, and can improve patient outcomes

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)使用经鼻高流量氧疗
(2)100mmhg<氧合指数(PO2/FiO2)≤200mmhg

Inclusion criteria

(1)Use high flow nasal oxygen therapy
(2)100mmhg

排除标准:

①年龄<18岁
②不能配合俯卧或拒绝俯卧的患者
③血流动力学不稳定(SBP<90mmHg, MBP < 65 mmHg 或需要使用血管活性药物的)
④胸、腹部有外伤、烧烫伤或手术的患者,怀孕的患者
⑤被医生评估需要立即插管的患者(出现神志改变,氧合指数迅速下降至100mmhg以下)
⑥气胸患者
⑦急性出血性疾病
⑧颅内压增高
⑨脊柱、脊髓损伤或需要限制非俯卧位体位的患者
⑩拒绝插管或抢救的患者

Exclusion criteria:

① <18 years old
② be not able to prone
③ hemodynamic instability (sbp <90mmhg, mbp <65 mmhg, or those with vasoactive drugs required)
④ patients with trauma, burns, or surgery in the chest and abdomen, pregnant patients
⑤ was evaluated by physicians who needed immediate intubation (with psychiatric change and oxygenation index rapidly falling below 100mmhg) Patients with
⑥ pneumothorax
⑦ acute hemorrhagic disease
⑧ intracranial hypertension Patients
⑨ spinal column, spinal cord injury, or who need to limit the non-prone position
⑩ refusal to intubation or rescued patients

研究实施时间:

Study execute time:

From 2022-02-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-24 00:00:00 To 2022-12-31 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

61

Group:

control group

Sample size:

干预措施:

半卧位联合经鼻高流量氧疗

干预措施代码:

Intervention:

Semi-supine position combines with high-flow nasal oxygen therapy

Intervention code:

组别:

试验组1

样本量:

61

Group:

experimental group A

Sample size:

干预措施:

俯卧位联合经鼻高流量氧疗

干预措施代码:

Intervention:

combine prone position with high flow nasal oxygen therapy

Intervention code:

组别:

试验组2

样本量:

61

Group:

experimental group B

Sample size:

干预措施:

侧卧位联合经鼻高流量氧疗

干预措施代码:

Intervention:

combine lateral position with high flow nasal oxygen therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆市 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆市第五人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Fifth People's Hospital of Chongqing

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

28天全因死亡率

指标类型:

主要指标

Outcome:

All-cause mortality in 28 days

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

28天气管插管率

指标类型:

次要指标

Outcome:

Intubation rate in 28 days

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧合指数的改变情况

指标类型:

次要指标

Outcome:

Change in the PaO2/FiO2 ratio

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

降钙素原改变情况

指标类型:

次要指标

Outcome:

Change in procalcitonin levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝素结合蛋白情况

指标类型:

次要指标

Outcome:

Change in heparin-binding protein levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉呼吸困难评分

指标类型:

次要指标

Outcome:

Visual analogue scale for dyspnea

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卧位改变时间

指标类型:

次要指标

Outcome:

Position changing time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ROX指数的改变

指标类型:

次要指标

Outcome:

Change in the ratio of SpO2/FiO2 to respiratory rate(ROX index)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

使用经鼻高流量氧疗、无创呼吸机或有创呼吸机时间

指标类型:

次要指标

Outcome:

Number of days using HFNO,non-invasive ventilation or invasive ventilation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

The incidence of adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总住院时间及RICU住院时间

指标类型:

次要指标

Outcome:

Length of hospital and RICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

分层区组随机

Randomization Procedure (please state who generates the random number sequence and by what method):

stratified block randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

网络平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

network platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例登记表和电子病历管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and EDC system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-01-20 09:29:10